Almirall promotes corporate volunteering with its new Act4All program. On October 20th, Almirall launched Act4All, a new corporate volunteering program developed in conjunction with the Hazloposible Foundation. The initiative makes it easier for company employees to participate in social and environmental projects aligned with sustainable development goals. Through the new internal portal, interested people can join projects related to health, education, job inclusion, the environment, and humanitarian action. Act4All connects directly with the company's culture and its motto Uncommon by Nature, structured around four main pillars: * Health for All: Health and well-being initiatives for vulnerable groups. * Skills for Good: Professional volunteering at the service of NGOs and social projects. * Sustainable by Nature: Direct actions to protect and care for the environment. * Global Solidarity: Solidarity responses and aid in humanitarian emergencies. With technical support from Hazloposible, the program connects Almirall professionals directly with social entities, turning the company's sustainability commitments into concrete actions with a real impact on the community. * This content was generated with the assistance of Artificial Intelligence. At Hazloposible, Voluntariado Corporativo is committed to responsible innovation: the result has been reviewed and edited by its team to ensure its accuracy and the elimination of bias, aligning it with its values of equity and diversity.

Rovi stock: Barron's gives Rovi stock an EUR 75.85 average target. Published on 10/20/2026 at 15:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS Rovi reports nine-month results on November 5, 2026. Rovi stock costs EUR 58.05 on October 20, 2026, up 0.78 percent versus the BME close. Analyst target and reporting date. * Eleven ratings put the average Rovi target at EUR 75.85 on October 19, 2026. * Rovi will publish first nine months 2026 results on November 5, 2026. * Rovi stock costs EUR 58.05 at Lang & Schwarz on October 20, 2026 at 3:37 p.m. CEST, 0.78 percent above the BME close, 33.05 percent below the 52-week high. * First-half 2026 revenue growth was 13.20 percent and gross margin expanded 6.50 percentage points. Rovi (ISIN ES0157261019) has an average analyst target of EUR 75.85 from 11 ratings, according to Barron's on October 19, 2026. The target stands 30.66 percent above Rovi stock's EUR 58.05 price at Lang & Schwarz on October 20, 2026 at 3:37 p.m. CEST, up 0.78 percent versus the BME close of EUR 57.60 on October 19, 2026. Discover more Invest in Stocks November 5 brings the next report. Rovi will publish its first nine months 2026 financial results on November 5, 2026, according to the company's investor calendar at Rovi. The date gives the market a defined checkpoint after the company's first-half 2026 report. Stock remains near its yearly low. Rovi's 52-week range was EUR 53.10 to EUR 86.70 on October 19, 2026. At EUR 58.05, the stock stood 9.32 percent above its low and 33.05 percent below its high. The stock's year-to-date performance was minus 9.29 percent. What does valuation show? Rovi carried a market capitalization of EUR 2.91 billion, a trailing price-to-earnings ratio of 15.91 and a dividend yield of 1.35 percent on October 19, 2026. Its first-half 2026 report showed total revenue growth of 13.20 percent and gross margin expansion of 6.50 percentage points, according to Rovi. Comparison with peers. Rovi: up 0.78 percent, P/E 15.91, market capitalization EUR 2.91 billion. Almirall (BME, EUR): up 2.10 percent, P/E 30.79, market capitalization EUR 2.22 billion. Grifols (BME, EUR): up 0.55 percent, P/E 15.17, market capitalization EUR 6.90 billion. Price and reporting dates. The analyst target provides the clearest valuation counterpoint to Rovi's 9.32 percent cushion above its 52-week low. The next scheduled company date is November 5, 2026, when the nine-month figures will add a fresh operating reference. Rovi stock was trading at EUR 58.05 at Lang & Schwarz on October 20, 2026 at 3:37 p.m. CEST, 0.78 percent above the BME close of October 19, 2026 at EUR 57.60. The further course of trading is shown by the continuously updated real-time quote of Rovi stock. Rovi stock key figures. * Company: Laboratorios Farmaceuticos Rovi, S.A. * ISIN: ES0157261019 * Ticker: ROVI.MC * Primary exchange: BME * Price Lang & Schwarz (as of October 20, 2026, 3:37 p.m. CEST): EUR 58.05 * Change versus BME close: plus 0.78 percent * BME close (October 19, 2026): EUR 57.60 * Market capitalization: EUR 2.91 billion (as of October 19, 2026) * 52-week range: EUR 53.10-EUR 86.70 (as of October 19, 2026) * Sector / Industry: Healthcare / specialty and generic drugs * Next earnings date: November 5, 2026 Discover more Track Biotech Read Economics Track Stock Market Sponsored Ad Laboratorios Farmaceuticos ROVI stock: new analysis - 23 October. Fresh Laboratorios Farmaceuticos ROVI information released. What's the impact for investors? Our latest independent report examines recent figures and market trends. Disclaimer regarding our articles: This is not investment advice, nor is it a recommendation to buy or sell. Information regarding prices, companies, and markets is provided without guarantee; changes may occur at any time. Stock market transactions can result in significant losses. Our articles are created and reviewed, in whole or in part, automatically with the assistance of AI. en | ES0157261019 | ROVI | boerse | 70374499 | bgmi

Almirall secures exclusive rights outside mainland China for CrystalO dermatology programme. (IN BRIEF) Almirall has entered into a collaboration and licensing agreement with CrystalO for the discovery and development of novel small molecules in medical dermatology. Under the agreement, CrystalO will handle candidate discovery, optimisation, IND-enabling studies and early clinical development, with the goal of achieving clinical proof of concept. Almirall will hold exclusive rights outside mainland China and will lead later-stage global development, manufacturing and commercialisation. The collaboration supports Almirall's strategy to strengthen its medical dermatology pipeline through external innovation, strategic partnerships and access to complementary R&D capabilities. (PRESS RELEASE) BARCELONA, 11-Aug-2026 - /EuropaWire/ - Almirall has entered into a collaboration and licensing agreement with CrystalO, a Chinese company focused on drug discovery, to identify and develop novel small molecules for use in medical dermatology. The partnership supports Almirall's broader innovation strategy, which includes identifying promising local research and development programmes that can complement the company's internal scientific capabilities. The agreement also reflects Almirall's continued focus on advancing differentiated treatments in dermatology, particularly in areas where patients continue to face significant unmet medical needs. Through strategic partnerships and scientific collaboration, Almirall aims to strengthen its pipeline and accelerate the development of new therapeutic options for skin conditions. Under the terms of the agreement, CrystalO will be responsible for candidate discovery, optimisation, IND-enabling studies and early clinical development. The objective is to advance selected candidates to clinical proof of concept. Almirall will hold exclusive rights outside mainland China. The company will also lead subsequent global development, manufacturing and commercialisation activities for the programme. Karl Ziegelbauer, Chief Scientific Officer at Almirall, said the collaboration with CrystalO represents another important step in advancing the company's innovation strategy in China. He said the agreement further strengthens Almirall's research and development pipeline in medical dermatology. Ziegelbauer added that Almirall sees potential in the discovery partnership to deliver meaningful benefits to patients living with skin conditions around the world. Dr Zhang Jin, Founder and Chief Executive Officer of CrystalO, said the company is honoured to enter into a strategic collaboration with Almirall, which he described as a leading company with a strong global reputation in dermatology. He said the partnership represents strong recognition of CrystalO's technology platform and its research and development capabilities in ion channel drug discovery. Dr Zhang added that CrystalO looks forward to working closely with Almirall, combining the strengths of both companies to accelerate the development of innovative medicines and bring benefits to patients worldwide as early as possible. Through the collaboration, Almirall is expanding its access to external innovation while strengthening its position in medical dermatology through a partnership focused on novel small molecules, ion channel drug discovery and global development opportunities. Media Contact: Media Relations Corporate Communications [email protected] T +34 932 91 35 08 MORE ON ALMIRALL, ETC.: EDITOR'S PICK: